RIDGEFIELD, Conn., March 29, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range of COPD ...
Patients whose asthma symptoms are only mild and intermittent usually don’t need daily asthma medications. They just use a rescue inhaler, like albuterol, whenever symptoms come up. Patients with ...
Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler is ...
Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...
Further tiotropium + olodaterol FDC data on patient outcomes such as quality of life are due to report later this year SAN DIEGO--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only ...
PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent ...
WASHINGTON, Sept 23 (Reuters) - The blockbuster inhaled lung medication Spiriva, marketed by Pfizer Inc and Boehringer Ingelheim, raises the risk of heart attack, stroke and death from heart disease, ...
Inhaler drugs used by millions of people with emphysema and bronchitis may slightly raise the risk for heart attacks and even death, a study suggests. The results aren't conclusive and inhalers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback